ReviewCurrent opinion in rheumatology2009
T-cell and B-cell signaling biomarkers and treatment targets in lupus.
Review in Current opinion in rheumatology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Anti-AHNAK1 Antibodies Are a Novel Diagnostic Biomarker for Systemic Lupus Erythematosus.BioMed research international · 2025Article
- Dynamics of CD4+ and CD8+ Lymphocytic Inflammatory Infiltrates in Lupus Nephritis.International journal of molecular sciences · 2024Article
- MDIC3: Matrix decomposition to infer cell-cell communication.Patterns (New York, N.Y.) · 2024Article
- Exploring the transcriptomic landscape of moyamoya disease and systemic lupus erythematosus: insights into crosstalk genes and immune relationships.Frontiers in immunology · 2024Article
- Biomarkers of Oxidative Stress in Systemic Lupus Erythematosus Patients with Active Nephritis.Antioxidants (Basel, Switzerland) · 2023Article
- B cell receptor repertoire analysis from autopsy samples of COVID-19 patients.Frontiers in immunology · 2023Article
- Mesenchymal stem cell-derived exosome-educated macrophages alleviate systemic lupus erythematosus by promoting efferocytosis and recruitment of IL-17Stem cell research & therapy · 2022Article
- Loss of Gut Barrier Integrity In Lupus.Frontiers in immunology · 2022Review
- P140 Peptide Leads to Clearance of Autoreactive Lymphocytes and Normalizes Immune Response in Lupus-Prone Mice.Frontiers in immunology · 2022Article
- lncRNA-CD160 decreases the immunity of CD8Oncology letters · 2020Article
- Sodium Butyrate Ameliorates Gut Microbiota Dysbiosis in Lupus-Like Mice.Frontiers in nutrition · 2020Article
- Pathogenesis and treatment of autoimmune rheumatic diseases.Current opinion in rheumatology · 2019Review
- Innate Immune Cells' Contribution to Systemic Lupus Erythematosus.Frontiers in immunology · 2019Review
- Comorbid connective tissue diseases and autoantibodies in lymphangioleiomyomatosis: a retrospective cohort study.Orphanet journal of rare diseases · 2018Article
- Support for phosphoinositol 3 kinase and mTOR inhibitors as treatment for lupus using in-silico drug-repurposing analysis.Arthritis research & therapy · 2017Article
- Oxidative Stress and Treg and Th17 Dysfunction in Systemic Lupus Erythematosus.Oxidative medicine and cellular longevity · 2016Review
- Mitochondria, calcium, and tumor suppressor Fus1: At the crossroad of cancer, inflammation, and autoimmunity.Oncotarget · 2015Review
- A novel NF-κB inhibitor, DHMEQ, ameliorates pristane-induced lupus in mice.Experimental and therapeutic medicine · 2014Article
- Serum- and glucocorticoid-induced protein kinase 1 (SGK1) is regulated by store-operated Ca2+ entry and mediates cytoprotection against necrotic cell death.The Journal of biological chemistry · 2013Article
- Metabolic regulation of organelle homeostasis in lupus T cells.Clinical immunology (Orlando, Fla.) · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purpose of reviewSystemic lupus erythematosus is characterized by the production of antinuclear autoantibodies and dysfunction of T-cells, B-cells, and dendritic cells. Here, we review newly recognized genetic factors and mechanisms that underlie abnormal intracellular signal processing and intercellular communication within the immune system in systemic lupus erythematosus. RECENT
findingsActivation of the mammalian target of rapamycin plays a pivotal role in abnormal activation of T and B-cells in systemic lupus erythematosus. In T-cells, increased production of nitric oxide and mitochondrial hyperpolarization were identified as metabolic checkpoints upstream of mammalian target of rapamycin activation. Mammalian target of rapamycin controls the expression T-cell receptor-associated signaling proteins CD4 and CD3zeta through increased expression of the endosome recycling regulator HRES-1/Rab4 gene, mediates enhanced Ca2+ fluxing and skews the expression of tyrosine kinases both in T and B-cells, and blocks the expression of Foxp3 and the expansion of regulatory T-cells. Mitochondrial hyperpolarization and the resultant ATP depletion predispose T-cells to necrosis, thus promoting the dendritic cell activation, antinuclear autoantibody production, and inflammation. SUMMARY: Mitochondrial hyperpolarization, increased activity of mammalian target of rapamycin and Syk kinases, enhanced receptor recycling and Ca2+ flux have emerged as common T and B-cell biomarkers and targets for treatment in systemic lupus erythematosus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.